What is IntegriChain?
IntegriChain operates as a comprehensive platform designed to streamline the complexities of therapy commercialization and market access. Its proprietary ICyte Platform is engineered to unify financial, operational, and commercial data sets, providing pharmaceutical manufacturers with the essential infrastructure for specialty and precision medicine. By leveraging IntegriChain's consulting expertise and advanced analytics, companies can digitalize their market access operations, enabling more data-driven decision support and enhancing patient access to critical therapies. The platform's capabilities are vital for navigating the evolving landscape of healthcare and pharmaceutical distribution.
How much funding has IntegriChain raised?
IntegriChain has raised a total of $8M across 2 funding rounds:
Series A
$2M
Private Equity
$6M
Series A (2006): $2M with participation from NJTC Venture Fund
Private Equity (2015): $6M led by SaaS Capital
Key Investors in IntegriChain
NJTC Venture Fund
TechUnited:NJ is a non-profit organization dedicated to empowering innovators and entrepreneurs in New Jersey. It provides a platform for networking, funding, and education to accelerate opportunities and propel ideas into action.
SaaS Capital
Saas Capital, founded in 2007, provides growth strategies and capital solutions, along with consulting services in areas such as market automation and business development.
What's next for IntegriChain?
With a significant enterprise-level funding context, IntegriChain is poised for accelerated expansion and further development of its ICyte Platform. The company's focus on digitalizing market access operations suggests a strategic direction towards enhancing data integration and business process automation. Future initiatives are likely to involve deepening its capabilities in payer contracting, patient services, and supply chain management, further solidifying its position as a leader in the pharmaceutical commercialization technology sector. Continued investment in data analytics and consulting services will be key to supporting pharmaceutical innovators in achieving optimal market access and therapy adoption.
See full IntegriChain company page
